Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

Phase 2Small molecule

JJohnson & Johnson Enterprise Innovation Inc.

Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel is one of 76 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Carcinoma, Non-Small-Cell LungRecruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Vizimpro

Pfizer

Preclinical

4 4

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 5

Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

JJohnson & Johnson Enterprise Innovation Inc.

Phase 2

1 6

Remeron

OOrganon and Co

Preclinical

1 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667908

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 2·NCT06667908·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Enterprise Innovation Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJohnson & Johnson Enterprise Innovation Inc.

Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News